ACR Convergence 2025| Video: Rheuminations on Milestones & Ageism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Articles tagged with "Osteoporosis"

Letter: Tips to Improve Osteoporosis Screening Rates

Timothy Harrington, MD  |  

Osteoporosis Screening The aphorism, “Those who do not learn history are doomed to repeat it,” applies to The Rheumatologist August 2017 article that documents the continued low screening rates for those at high risk for osteoporosis-related fragility fractures, in particular people older than 65 and those who have suffered a fracture already. So here’s a…

New Data May Explain the Role of Sclerostin in Bone Formation

  |  

New research in mice shows that sclerostin deficiency may play a significant role in bone formation, possibly despite skeletal age. In the study, sclerostin-deficient mice more readily formed cortical bone and had increases in periosteal bone formation rates, as well as increased expression of the Wnt inhibitor Dkk1, than controls…

Undetected Fractures Linked to Back Pain in Older Men

Shereen Lehman  |  

(Reuters Health)—About three in five older men with tiny spinal fractures related to osteoporosis reported new or worsening back pain in a new study. Only about one-quarter of new vertebral fractures are diagnosed by a doctor, the study team writes in their September 7 online report in Journal of Bone and Mineral Research, though the…

Switching from Bisphosphonates to Teriparatide May Improve BMD in Women with RA

Scott Baltic  |  

NEW YORK (Reuters Health)—Switching women with rheumatoid arthritis (RA) from oral bisphosphonates to teriparatide increases bone mineral density (BMD) and trabecular bone score, according to a new report. Researchers in Japan conducted an 18-month observational study of more than 175 women with RA (mean age: 66) who remained on oral bisphosphonates, switched to denosumab (DMAb),…

Osteoporosis Screening Is Underutilized Despite Recommendations

Osteoporosis Screening Is Underutilized Despite Recommendations

  |  

For years, guidelines from various organizations have recommended osteoporosis screening in women and men starting at a specific age or based on specific risk factors. Among these guidelines are those developed by the U.S. Preventive Services Task Force (USPSTF) that recommend universal osteoporosis screening for women 65 years of age and older and for targeted…

Novel Bone Drug Promising in Postmenopausal Osteoporosis

Reuters Staff  |  

NEW YORK (Reuters Health)—The investigational drug romosozumab led to gains in hip bone mineral density (BMD) that were not seen with teriparatide in older women with osteoporosis transitioning from bisphosphonate therapy in the STRUCTURE study. Amgen’s romosozumab is a monoclonal antibody that inhibits sclerosin, a negative regulator of bone formation. In addition to stimulating bone…

Rheumatology Drug Updates: Uncertain Future for Romosozumab, Plus FDA Approves Tocilizumab for GCA

  |  

Romosozumab’s Future Is Uncertain Romosozumab, which has the possible U.S. brand name Evenity, is awaiting approval from the FDA.1 The treatment is an investigational, injectable biologic for treating osteoporosis. It increases bone formation and bone density, reducing a patient’s risk of fractures. The manufacturer no longer expects the FDA to approve the drug this year…